Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.06.16.20132878: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources In addition, we searched Google Scholar and the references of eligible studies and review articles. Google Scholarsuggested: (Google Scholar, RRID:SCR_008878)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Strength and Limitations: Our meta-analysis is the …
SciScore for 10.1101/2020.06.16.20132878: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources In addition, we searched Google Scholar and the references of eligible studies and review articles. Google Scholarsuggested: (Google Scholar, RRID:SCR_008878)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Strength and Limitations: Our meta-analysis is the first comprehensive systematic review examining the risk of QT prolongation and its associated adverse events in COVID-19 patients treated with CQ/HCQ. However, like any meta-analysis, it has several limitations. First, the retrospective nature of most of the included studies make them prone to incomplete or missing data. Second, there were variations in the variables collected by individual studies particularly related to reporting QTc parameters and adverse events and significant differences in the patient populations enrolled by these studies. This may have resulted in underreporting of certain important endpoints like TdP. For example, the study by Rosenberg et al listed all arrhythmias under one group with a frequency of 19.3%. This study also reported high incidence of cardiac arrest of 15%, hence, it’s very possible that some cases with TdP would have been included in the arrhythmia or cardiac arrest groups. Third, there was marked heterogeneity in our pooled estimates; however, we performed a meta-regression that allowed us to identify contributors to the observed heterogeneity and further determine populations at risk for CQ/HCQ induced QT prolongation, which further strengthens our study and its conclusions. Implications for Ongoing Randomized Clinical Trials: A recent randomized, double-blind, placebo-controlled trial across the United States and parts of Canada tested HCQ as post-exposure prophylaxis. After high-r...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
